Revenue: As of FY2026 Q2, the actual value is USD 190.7 M, missing the estimate of USD 206.03 M.

EPS: As of FY2026 Q2, the actual value is USD -0.46.

EBIT: As of FY2026 Q2, the actual value is USD -35.2 M.

The provided Form 8-K for Myriad Genetics, Inc. indicates that the company announced its financial results for the three months ended June 30, 2026, on July 30, 2026. However, the detailed financial results and forward-looking statements, which are contained in Exhibit 99.1, are not included in the provided reference text. Consequently, specific financial metrics such as segment revenue, net income, gross margin, operating profit, operating costs, operating cash flow, free cash flow, unique company-specific indicators, or any detailed outlook/guidance cannot be extracted from this document.